SYRS - Syros Pharmaceuticals GAAP EPS of -$3.21 beats by $0.30 revenue of $3.9M misses by $1.28M
- Syros Pharmaceuticals press release ( NASDAQ: SYRS ): Q3 GAAP EPS of -$3.21 beats by $0.30 .
- Revenue of $3.9M (-31.6% Y/Y) misses by $1.28M .
- The company expects that its existing cash, cash equivalents and marketable securities of $244.5M will be sufficient to fund its planned operating expenses and capital expenditure requirements into 2025.
For further details see:
Syros Pharmaceuticals GAAP EPS of -$3.21 beats by $0.30, revenue of $3.9M misses by $1.28M